Datamonitor’s “Merck KGaA: PharmaVitae Report” is now available at ReportsnReports.com.

1. Merck KGaA: PharmaVitae Report
Introduction
This analysis examines the historical and forecast performance for Merck KGaA in the
prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio
and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for
key drugs.
Features and benefits
 Analyze company sales forecasts by product, therapy area, lifecycle stage, geography,
molecule type and source.
 Gain insight into Merck KGaA's strategic outlook across the next 6 years.
Highlights
Strategic insight into the prospects for Merck KGaA report over the next six years. Picking
out key strengths, weaknesses, opportunities and threats and evaluating the company's
prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Table Of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Sales analysis
Financial analysis
Product analysis
Data sourcing
Analyst consensus
EXECUTIVE SUMMARY
Key findings
Merck KGaA prescription pharma sales outlook
Merck KGaA financial outlook
Key developments
(Untitled sub-section)
SWOT analysis

2. Strengths
Weaknesses
Opportunities
Threats
STRATEGIC INSIGHT
Key findings
Strategic restructure
Erbitux and Serono acquisition rejuvenate branded pharmaceuticals business…
and diversify Merck KGaA’s portfolio to improve long-term prospects
Restructuring bolsters financial performance
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
(Untitled sub-section)
Acquisition of Millipore
Current corporate structure
Pharmaceuticals
Chemicals
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis

3. FINANCIAL ANALYSIS
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-
reported total sales, 2004–10
Operating costs and profit analysis
Operating costs and profit analysis, 2004–10
Operating cost ratio and profit margin analysis, 2004–10
Operating cost ratio and profit margin analysis, 2010–16
Operating costs and profit analysis, 2010–16
PRODUCT ANALYSIS
Overview
Erbitux
Rebif
Merck KGaA pipeline overview
APPENDIX
References
Datamonitor reports
Exchange rates
LIST OF TABLES
Table: Merck KGaA – key product overview ($m), 2010–16
Table: Merck KGaA’s financial performance ($m), 2010–16
Table: Merck KGaA product portfolio overview ($m), 2004–10
Table: Merck KGaA product portfolio overview ($m), 2010–16
Table: Merck KGaA prescription pharmaceutical sales, by therapy area ($m), 2010–16
Table: Merck KGaA prescription pharmaceutical sales, by geographic region ($m), 2010–16
Table: Merck KGaA launch portfolio overview ($m), 2010–16
Table: Merck KGaA core portfolio overview ($m), 2010–16
Table: Merck KGaA expiry portfolio overview ($m), 2010–16
Table: Merck KGaA prescription pharmaceutical sales, by molecule type ($m), 2010–16
Table: Merck KGaA prescription pharmaceutical sales, by source ($m), 2010–16
Table: Total Merck KGaA sales, by business unit ($m), 2004–10
Table: Merck KGaA operating revenues, costs, and profit ($m), 2004–10
Table: Merck KGaA operating cost ratios and profit margin (as a percentage of total revenues),
2004–10
Table: Merck KGaA operating cost ratios and profit margin (as a percentage of total revenues),
2010–16
Table: Merck KGaA operating revenues, costs, and profit ($m), 2010–16

4. Table: Key product sales ($m), 2010–16
Table: Erbitux: overview
Table: Erbitux: sales forecast ($m), 2010–16
Table: Rebif: overview
Table: Rebif: sales forecast ($m), 2010–16
Table: Merck KGaA’s R&D pipeline
Table: Exchange rates, 2011
LIST OF FIGURES
Figure: The PharmaVitae Explorer
Figure: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate
(%), 2004–16
Figure: Merck KGaA operating revenues, costs, and profit ($m), 2004–16
Figure: Merck KGaA SWOT analysis
Figure: Merck KGaA’s (pre-Serono acquisition) biologics focus (percentage of pharmaceutical
sales), 2004 and 2007
Figure: Merck KGaA’s therapeutic focus (percentage of branded ethical sales), 2004, 2010, and
2016
Figure: Merck KGaA’s revenue split, 2004–16
Figure: Current corporate structure
Figure: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate
(%), 2004–16
Figure: Merck KGaA’s key product sales ($m), 2004–16
Figure: Merck KGaA key sales growth drivers and resistors ($m), 2004–10
Figure: Merck KGaA key sales growth drivers and resistors ($m), 2010–16
Figure: Merck KGaA prescription pharmaceutical sales, by therapy area ($m), 2004–16
Figure: Merck KGaA prescription pharmaceutical sales, by geographic region ($m), 2004–16
Figure: Merck KGaA launch/core/expiry configuration ($m), 2010–16
Figure: Merck KGaA prescription pharmaceutical sales, by molecule type ($m), 2004–16
Figure: Merck KGaA prescription pharmaceutical sales, by source ($m), 2004–16
Figure: Merck KGaA operating revenues, costs, and profit ($m), 2004–16
Figure: Erbitux sales, by geographic region ($m), 2004–16
Figure: Rebif sales, by geographic region ($m), 2004–16
Figure: Merck KGaA’s pipeline, by therapy area

5. About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog